To investigate the role of metabotrophic purinergic P2Y receptors in neuroblastoma cell survival, expression of P2 receptors by normal mouse (C57BL/6) brain and human neuroblastoma SH-SY5Y cells was investigated by Western blot and real time PCR studies. Viability of SH-SY5Y cells treated with purinergic receptor antagonists suramin and pyridoxal-phosphate-6-azophenyl-2’,4’-disulfonate (PPADS) was evaluated by MTT assay and flow cytometry. In the brain samples of C57BL/6 mice, expressions of P2Y4 and P2X7 were significantly reduced, whereas that of P2Y1 was significantly elevated in an age-dependent manner. SH-SY5Y cell viability was significantly reduced and necrotic cell rates were mildly increased by 400 μM suramin and 100 μM PPADS treatment. Antagonist treatment downregulated P2Y1, P2Y2 and P2Y4 and upregulated P2Y6, P2Y12 and P2X7 mRNA levels in SH-SY5Y cells on the 24th hour. These alterations were abolished for all P2 receptors except P2Y1 in the 48th hour. P2Y receptors are expressed by both normal mouse brain and human neuroblastoma cells. Purinergic receptor antagonism interferes with neuroblastoma viability through elevation of necrotic cell death and modulation of P2 receptor expression. P2Y receptors might thus be useful targets for future anti-tumor treatment trials.
Apolloni, S., Finocchi, P., D’Agnano, I. et al. (2010) UDP exerts cytostatic and cytotoxic actions in human neuroblastoma SH-SY5Y cells over-expressing P2Y6 receptor. Neurochem. Int. 56, 670–678.
Bernier, L. P., Ase, A. R., Séguéla, P. (2013) Post-translational regulation of P2X receptor channels: modulation by phospholipids. Front. Cell. Neurosci. 7, 226.
Bianchi, G., Vuerich, M., Pellegatti, P. et al. (2014) ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell. Death. Dis. 5, e1135.
Cavaliere, F., Nestola, V., Amadio, S. et al. (2005) The metabotropic P2Y4 receptor participates in the commitment to differentiation and cell death of human neuroblastoma SH-SY5Y cells. Neurobiol. Dis. 18, 100–109.
Gómez-Villafuertes, R., García-Huerta, P., Díaz-Hernández, J. I., Miras-Portugal, M. T. (2015) PI3K/Akt signaling pathway triggers P2X7 receptor expression as a pro-survival factor of neuroblastoma cells under limiting growth conditions. Sci. Rep. 5, 18417.
Kehasse, A., Rich, C. B., Lee, A. et al. (2013) Epithelial wounds induce differential phosphorylation changes in response to purinergic and EGF receptor activation. Am. J. Pathol. 183, 1841–1852.
Larsson, K. P., Hansen, A. J., Dissing, S. (2002) The human SH-SY5Y neuroblastoma cell-line expresses a functional P2X7 purinoceptor that modulates voltage-dependent Ca2+ channel function. J. Neurochem. 83, 285–298.
McConville, C. M., Forsyth, J. (2003) Neuroblastoma–a developmental perspective. Cancer. Lett. 197, 3–9.
Miao, L. Y., Tang, J. P., Esposito, D. P., Zhang, J. H. (2001) Age-related changes in P2 receptor mRNA of rat cerebral arteries. Exp. Gerontol. 37, 67–79.
North, R. A. (2002) Molecular physiology of P2X receptors. Physiol. Rev. 82, 1013–1067.
Puchalowicz, K., Tarnowski, M., Baranowska-Bosiacka, I., Chlubek, D., Dziedziejko, V. (2014) P2X and P2Y receptors–role in the pathophysiology of the nervous system. Int. J. Mol. Sci. 15, 23672–23704.
Raffaghello, L., Chiozzi, P., Falzoni, S., Di Virgilio, F., Pistoia, V. (2006) The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer. Res. 66, 907–914.
Tsuda, M., Toyomitsu, E., Kometani, M., Tozaki-Saitoh, H., Inoue, K. (2009) Mechanisms underlying fibronectin-induced up-regulation of P2X4R expression in microglia: distinct roles of PI3K-Akt and MEK-ERK signalling pathways. J. Cell. Mol. Med. 13, 3251–3259.
Woods, L. T., Ajit, D., Camden, J. M., Erb, L., Weisman, G. A. (2016) Purinergic receptors as potential therapeutic targets in Alzheimer’s disease. Neuropharmacology 104, 169–179.
Yaguchi, T., Saito, M., Yasuda, Y., Kanno, T., Nakano, T., Nishizaki, T. (2010) Higher concentrations of extracellular ATP suppress proliferation of Caco-2 human colonic cancer cells via an unknown receptor involving PKC inhibition. Cell. Physiol. Biochem. 26, 125–134.
About this article
Cite this article
Örçen, A., Yılmaz, V., Giriş, M. et al. Viability of SH-SY5Y Cells is Associated with Purinergic P2 Receptor Expression Alterations. BIOLOGIA FUTURA 68, 22–34 (2017). https://doi.org/10.1556/018.68.2017.1.3
- purinergic receptor